Crucial win for Biocon as FDA approves cancer biosimilar trastuzumab 2017-12-022017-12-02 | Trisha Thomas
EU accepts Biocon, Mylan’s application for cancer biosimilar pegfilgrastim 2017-12-012017-12-01 | Trisha Thomas
Biocon, Mylan apply again for EU approval for cancer drugs trastuzumab, pegfilgrastim 2017-11-072017-11-07 | Trisha Thomas
Biocon’s European approval for cholesterol drug opens $1.2 billion market 2016-02-152016-02-15 | Sanjay Kumar